Stock Events

Stock Events

Evofem Biosciences 

€0.000000
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

19AugExpected
Q4 2024
Next
-0.03
0.31
0.64
0.97
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1AQ1.MU. It's not an investment recommendation.
Tesla
19
TSLA
Apple
16
AAPL
Amazon
13
AMZN
NIO
13
NIO

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap138.61B
Pfizer offers a range of contraceptives and women's health products, directly competing with Evofem's contraceptive solutions.
Merck
MRK
Mkt Cap319.99B
Merck produces various contraceptives and women's health products, making it a direct competitor to Evofem Biosciences.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap40.34B
Teva Pharmaceutical Industries offers generic and specialty medicines, including contraceptives, competing in the same space as Evofem.
Johnson & Johnson
JNJ
Mkt Cap633.19B
Johnson & Johnson, through its pharmaceutical division, offers products in women's health, including contraceptives, competing with Evofem.
Abbvie
ABBV
Mkt Cap461.26B
AbbVie, having acquired Allergan, competes in the women's health and contraceptives market, overlapping with Evofem's offerings.
Lilly(Eli) &
LLY
Mkt Cap1.08T
Eli Lilly, while primarily focused on other areas, has interests in women's health that could position it as a competitor to Evofem.
Novo Nordisk
NVO
Mkt Cap223.19B
Novo Nordisk, with its focus on chronic diseases, has shown interest in expanding into women's health, potentially competing with Evofem.
AMGEN
AMGN
Mkt Cap201.93B
Amgen, primarily known for biopharmaceuticals, has the potential to enter the women's health market, posing a future competitive threat to Evofem.

About

Evofem Biosciences, Inc. operates as a biopharmaceutical enterprise dedicated to innovating and bringing to market treatments that address critical underserved areas in women's sexual and reproductive health. Their leading commercial offering is Phexxi, a vaginal gel specifically designed as a contraceptive. Additionally, the company is actively advancing EVO100, an antimicrobial vaginal gel under development, intended to prevent the urogenital spread of both Chlamydia trachomatis and Neisseria gonorrhoeae infections in women. The company's main office is situated in San Diego, California.
Show more...
CEO
Ms. Saundra Pelletier
Employees
32
Country
United States
ISIN
US30048L1044

Listings

MU
DE
1AQ1.MU
STU
DE
1AQ1.STU
OTC Link
US
EVFM

0 Comments

Share your thoughts

FAQ

What is Evofem Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Evofem Biosciences stocks are traded under the ticker 1AQ1.MU.
When is the next Evofem Biosciences earnings date?▼
Evofem Biosciences is going to release the next earnings report on August 19, 2026.
What were Evofem Biosciences earnings last quarter?▼
1AQ1.MU earnings for the last quarter are -0.03 EUR per share, whereas the estimation was N/A EUR resulting in a N/A surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Evofem Biosciences have?▼
As of July 09, 2026, the company has 32 employees.
In which sector is Evofem Biosciences located?▼
Evofem Biosciences operates in the Health & Wellness sector.
When did Evofem Biosciences complete a stock split?▼
Evofem Biosciences has not had any recent stock splits.
Where is Evofem Biosciences headquartered?▼
Evofem Biosciences is headquartered in San Diego, United States.